Phio Pharmaceuticals

Phio Pharmaceuticals Corp. completed enrollment of its second patient cohort in the PH-762 Phase 1b trial, adding a sixth site in San Diego. One patient with cutaneous squamous cell carcinoma achieved a complete response, and another with squamous cell carcinoma achieved a partial response. The trial aims to evaluate the safety and tolerability of PH-762, an INTASYL siRNA compound targeting PD-1, in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.

Phio Pharmaceuticals Corp. to present at Renmark Financial Communications Inc.'s Virtual Non-Deal Roadshow on Oct 23, 2024, at 12 PM EDT. CEO Robert Bitterman will discuss the company's INTASYL siRNA technology designed to enhance immune cells' tumor-killing abilities.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) to present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. on October 23, 2024, at 12 PM EDT. The event will feature CEO Robert Bitterman discussing the company's INTASYL siRNA gene silencing technology designed to enhance immune cells' ability to kill tumor cells.

Phio Pharmaceuticals presents data on INTASYL's role in enhancing immune cell efficacy against cancer, including improved adoptive cell therapy outcomes. INTASYL compounds, like PH-762 and PH-894, silence specific genes to boost immune responses and tumor cell death.

Phio Pharmaceuticals Corp. presents data on its INTASYL self-delivering RNAi technology, enhancing cell potency and yield in adoptive cell therapy at the CAR-TCR Summit in Boston, MA on September 17th.